ASX:RGS Regeneus (RGS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Regeneus Stock (ASX:RGS) 30 days 90 days 365 days Advanced Chart Get Regeneus alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume13,076 shsAverage VolumeN/AMarket Capitalization$3.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRegeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.Read More… Receive RGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneus and its competitors with MarketBeat's FREE daily newsletter. Email Address RGS Stock News HeadlinesRegeneus Ltd. Announces Director Departure and Shareholding DetailsMay 22, 2025 | tipranks.comCambium Bio Limited Appoints New Director to Strengthen LeadershipMay 22, 2025 | tipranks.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 16, 2025 | Investors Alley (Ad)Cambium Bio Gains FDA Approval for Elate Ocular® Phase 3 Trial AssayMarch 17, 2025 | tipranks.comCambium Bio Limited Aligns Leadership Interests with Share IssuanceMarch 12, 2025 | tipranks.comCambium Bio Limited Successfully Passes All Resolutions at General MeetingMarch 4, 2025 | tipranks.comCambium Bio Addresses Compliance OversightMarch 2, 2025 | tipranks.comCambium Bio Limited Appoints New DirectorFebruary 17, 2025 | tipranks.comSee More Headlines RGS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Regeneus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneus investors own include American Rebel (AREB), Pacific Biosciences of California (PACB), DocuSign (DOCU), SuperCom (SPCB), Zion Oil & Gas (ZNOG), CASI Pharmaceuticals (CASI) and Carvana (CVNA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolASX:RGS CIKN/A Webregeneus.com.au Phone61 2 9499 8010FaxN/AEmployees630Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.69 million Net Margins-37.03% Pretax MarginN/A Return on Equity455.81% Return on Assets-62.56% Debt Debt-to-Equity Ratio-19.12 Current Ratio0.28 Quick Ratio0.46 Sales & Book Value Annual Sales$1.02 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow21.67 Book ValueA($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares306,440,000Free FloatN/AMarket Cap$3.68 million OptionableNot Optionable Beta-0.24 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (ASX:RGS) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneus Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
